1186482-11-0

Basic information

• Product Name: 1-bromo-4-propoxy-2-(trifluoromethyl)benzene
• Synonyms: 1-bromo-4-propoxy-2-(trifluoromethyl)benzene
• CAS NO: 1186482-11-0
• Molecular Weight: 283.088
• Mol File: 1186482-11-0.mol
• Article Data: 4

Chemical Properties

• CAS DataBase Reference: 1-bromo-4-propoxy-2-(trifluoromethyl)benzene(CAS DataBase Reference)
• NIST Chemistry Reference: 1-bromo-4-propoxy-2-(trifluoromethyl)benzene(1186482-11-0)
• EPA Substance Registry System: 1-bromo-4-propoxy-2-(trifluoromethyl)benzene(1186482-11-0)

Safety Data

• Hazardous Substances Data: 1186482-11-0(Hazardous Substances Data)

Upstream product

• 320-49-0 3-trifluoromethyl-4-bromophenol 
• 106-94-5 propyl bromide 
• 71-23-8 propan-1-ol 
• 40161-55-5 1-bromo-4-fluoro-2-(trifluoromethyl)benzene 
• 107-08-4 1-iodo-propane 

Downstream Products

• 1186482-51-8 (4-propoxy-2-(trifluoromethyl)phenyl)boronic acid 
• 1234790-81-8 4-(propyloxy)-2-(trifluoromethyl)benzaldehyde 
• 1234791-00-4 C₁₆H₁₈F₃NO₃ 
• 1234790-98-7 C₁₄H₁₄F₃NO₃ 
• 1234790-82-9 5-chloromethyl-3-(4-propoxy-2-trifluoromethyl-phenyl)-isoxazole 
• 1234790-99-8 C₁₄H₁₂F₃NO₃ 
• 1234790-92-1 1-ethynyl-4-propoxy-2-trifluoromethyl-benzene 
• 1268383-48-7 2-[(2-hydroxyethyl)oxy]ethyl [2-(2,3-difluorophenyl)-5H-imidazo[4,5-d]pyridazin-5-yl]{3-[4-(propyloxy)-2-(trifluoromethyl)phenyl]-5-isoxazolyl}acetate 
• 1268383-41-0 methyl [2-(2,3-difluorophenyl)-5H-imidazo[4,5-d]pyridazin-5-yl]{3-[4-(propyloxy)-2-(trifluoromethyl)phenyl]-5-isoxazolyl}-acetate 
• 1268385-34-7 methyl {3-[4-(Propyloxy)-2-(trifluoromethyl)phenyl]-5-isoxazolyl}acetate 
• 1268385-33-6 {3-[4-(propyloxy)-2-(trifluoromethyl)phenyl]-5-isoxazolyl}-acetic Acid 
• 1268385-32-5 2-{3-[4-(propyloxy)-2-(trifluoromethyl)phenyl]-5-isoxazolyl}-ethanol 
• 1234790-83-0 4-(propyloxy)-2-(trifluoromethyl)benzaldehyde oxime 
• 1186482-12-1 4-propoxy-2-((trifluoromethyl)phenyl)boronic acid pinacol ester 

Relevant articles and documents

Piperazine oxadiazole inhibitors of acetyl-CoA carboxylase

Acetyl-CoA carboxylase (ACC) is a target of interest for the treatment of metabolic syndrome. Starting from a biphenyloxadiazole screening hit, a series of piperazine oxadiazole ACC inhibitors was developed. Initial pharmacokinetic liabilities of the piperazine oxadiazoles were overcome by blocking predicted sites of metabolism, resulting in compounds with suitable properties for further in vivo studies. Compound 26 was shown to inhibit malonyl-CoA production in an in vivo pharmacodynamic assay and was advanced to a long-term efficacy study. Prolonged dosing with compound 26 resulted in impaired glucose tolerance in diet-induced obese (DIO) C57BL6 mice, an unexpected finding.

ANTI-VIRAL COMPOUNDS, COMPOSITIONS, AND METHODS OF USE

Disclosed are compounds of Formula (I), pharmaceutically acceptable salts thereof, compositions thereof, and methods for their preparation and uses for treating viral infections mediated at least in part by a virus in the Flaviviridae family of viruses.